US OptionsDetailed Quotes
TSVT240517P7500
- 2.50
- 0.000.00%
15min DelayClose Apr 16 09:44 ET
0.00High0.00Low
0.00Open2.50Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV9.89%PremiumMay 17, 2024Expiry Date2.95Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.82Leverage Ratio--Theta--Rho--Eff Leverage--Vega
2seventy bio Stock Discussion
Sign in to post a comment
$2seventy bio(TSVT.US$ 2Seventy Bio Inc: Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated Approximately $52 Mln in U.S. Revenue During Q1 of 2024
7
🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
11
2
$2seventy bio(TSVT.US$ Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
WSJ· 2 mins ago
Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, ...
WSJ· 2 mins ago
Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, ...
1
$2seventy bio(TSVT.US$ At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard Regimens
3
$2seventy bio(TSVT.US$ 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronApril 1, 2024 at 7:30 AM EDTPDF Version
- Company Now Exclusively Focused on Development and Commercialization of Abecma -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all onc...
- Company Now Exclusively Focused on Development and Commercialization of Abecma -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all onc...
1
$2seventy bio(TSVT.US$ +
(HOLO-LYT-PIXY...) KEEP BUYING, THEN THEY MUST GO DOWN (TO $1 AND DELETE) BECAUSE CHEATERS BLOCK SHORT = LAO TRAP TRADERS ONE WAY TO HELL 😭👹😡👊👎
(HOLO-LYT-PIXY...) KEEP BUYING, THEN THEY MUST GO DOWN (TO $1 AND DELETE) BECAUSE CHEATERS BLOCK SHORT = LAO TRAP TRADERS ONE WAY TO HELL 😭👹😡👊👎
No comment yet
JESSE JAMES8832 : quite a bit better than expected right?
JESSE JAMES8832 : 13.9m was the prediction
TrytosaveabitOP JESSE JAMES8832: I believe so yes?
TrytosaveabitOP JESSE JAMES8832: That rings a bell!
JESSE JAMES8832 : damn i thought this would do much better... short attack?
View more comments...